Form 4: Gilead CEO O'Day Reports Equity Transactions

Gilead Sciences CEO Daniel O'Day reported multiple equity transactions, including RSU vesting, stock sales for tax, and new RSU and stock option grants.

Summary

• Daniel Patrick O'Day, Chairman & CEO of Gilead Sciences, Inc. (GILD), reported changes in his beneficial ownership of company securities.
• On March 10, 2026, 20,026 shares of common stock were acquired through the vesting of restricted stock units (RSUs).
• Concurrently, 9,767 shares of common stock were disposed of at a price of $148.56 per share, likely for tax withholding purposes related to the RSU vesting.
• Following these transactions, O'Day beneficially owns 652,567 shares of common stock.
• 20,026 Restricted Stock Units (RSUs) were exercised/vested on March 10, 2026.
• An additional 32,815 Restricted Stock Units (RSUs) were acquired on March 10, 2026, bringing the total beneficially owned RSUs to 100,859.
• 122,755 Non-qualified Stock Options were acquired on March 10, 2026, with an exercise price of $148.56 and an expiration date of March 10, 2036.
• Both the newly acquired RSUs and stock options have a four-year vesting schedule: 25% vest on the first anniversary of the grant date, with the balance vesting 6.25% quarterly thereafter until fully vested.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, reflecting routine executive compensation and tax-related transactions, which align management interests with shareholders through new equity grants.

Positives

• The acquisition of 32,815 new Restricted Stock Units (RSUs) and 122,755 Non-qualified Stock Options aligns the CEO's long-term incentives with shareholder value creation.
• The vesting of 20,026 RSUs demonstrates the realization of previously granted equity compensation.

Negatives

• The disposition of 9,767 shares of common stock, although likely for tax purposes, reduces the CEO's direct share ownership.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance, as it is a report of insider transactions.

Industry Context

StockSavvy.ai notes that these transactions are typical for executive compensation packages in the pharmaceutical and biotechnology sectors, involving a mix of performance-based equity awards like RSUs and stock options to incentivize long-term leadership and align executive interests with shareholder returns.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and Non-qualified Stock Options with multi-year vesting schedules is a standard practice for executive compensation in large-cap biotech companies, comparable to practices at peers like Amgen or Biogen.
• The four-year vesting schedule, with an initial 25% vesting and subsequent quarterly vesting, is a common structure designed to promote executive retention and long-term commitment.
• The sale of shares to cover tax obligations upon RSU vesting is a routine and expected event, consistent with compensation practices across the industry.

Stakeholder Impact

• Shareholders: The new grants of RSUs and stock options further align the CEO's financial interests with the long-term performance of the company, potentially benefiting shareholders through sustained strategic focus.
• Employees: These transactions reflect standard executive compensation practices, which may influence broader compensation strategies within the company.

Next Steps

• The remaining unvested portions of the newly granted Restricted Stock Units and Non-qualified Stock Options will vest according to their four-year schedule, with 25% vesting on the first anniversary of the grant date and 6.25% quarterly thereafter.

Key Dates

Recommendation

This Form 4 details routine insider transactions related to executive compensation, including the vesting of restricted stock units, the sale of shares for tax purposes, and new grants of RSUs and stock options. These transactions are standard and do not indicate a change in the company's fundamental outlook or the executive's confidence beyond the standard compensation structure. Therefore, a 'hold' recommendation is appropriate as the filing itself does not provide new information to alter an existing investment thesis.

Keywords

Gilead Sciences, GILD, Insider Transaction, Form 4, Restricted Stock Units, Stock Options, Executive Compensation, Equity Awards, Beneficial Ownership